Angiogenesis inhibitors in gastric and gastroesophageal junction cancer

被引：0
|
作者：
Giandomenico Roviello
Roberto Petrioli
Luigi Marano
Karol Polom
Daniele Marrelli
Armando Perrella
Franco Roviello
机构：
[1] University of Siena,Medical Oncology Unit
[2] University of Siena,Unit of General and Minimally Invasive Surgery, Department of Medical, Surgical and Neuroscience
[3] University of Siena,Section of Advanced Surgical Oncology, Department of Medical, Surgical and Neurosciences
来源：
Gastric Cancer | 2016年 / 19卷
关键词：
Gastric cancer; VEGF; Bevacizumab; Ramucirumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Despite significant improvements in systemic chemotherapy during the past two decades, the prognosis of patients with advanced gastric and gastroesophageal junction adenocarcinoma remains poor. Because of molecular heterogeneity, it is essential to classify tumors based on the underlying oncogenic pathways and to develop targeted therapies acting on individual tumors. Unfortunately, although a number of molecular targets have been studied, very few of these agents can be used in a clinical setting. In this review, we summarize the available data on anti-angiogenic agents in advanced/metastatic gastric cancer.
引用
收藏
页码：31 / 41
页数：10
相关论文
共 50 条
  • [1] Angiogenesis inhibitors in gastric and gastroesophageal junction cancer
    Roviello, Giandomenico
    Petrioli, Roberto
    Marano, Luigi
    Polom, Karol
    Marrelli, Daniele
    Perrella, Armando
    Roviello, Franco
    [J]. GASTRIC CANCER, 2016, 19 (01) : 31 - 41
  • [2] Palliative Surgery for Patients with Gastroesophageal Junction and Gastric Cancer
    Song, Yun
    Chen, Eunise C.
    Bruera, Eduardo
    Ikoma, Naruhiko
    Mansfield, Paul F.
    Badgwell, Brian D.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2023, 237 (05) : S211 - S212
  • [3] Two decades of gastric and gastroesophageal junction cancer surgery
    Patrick S. Plum
    Aylin Pamuk
    Atakan G. Barutcu
    Christoph Mallmann
    Emanuel Niesen
    Felix Berlth
    Thomas Zander
    Seung-Hun Chon
    Stefan P. Moenig
    Alexander Quaas
    Christiane J. Bruns
    Arnulf H. Hoelscher
    Hakan Alakus
    [J]. Journal of Cancer Research and Clinical Oncology, 2023, 149 : 7679 - 7688
  • [4] Molecular targeted agents for gastric and gastroesophageal junction cancer
    Oshima, Takashi
    Masuda, Munetaka
    [J]. SURGERY TODAY, 2012, 42 (04) : 313 - 327
  • [5] Two decades of gastric and gastroesophageal junction cancer surgery
    Plum, Patrick S.
    Pamuk, Aylin
    Barutcu, Atakan G.
    Mallmann, Christoph
    Niesen, Emanuel
    Berlth, Felix
    Zander, Thomas
    Chon, Seung-Hun
    Moenig, Stefan P.
    Quaas, Alexander
    Bruns, Christiane J.
    Hoelscher, Arnulf H.
    Alakus, Hakan
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (10) : 7679 - 7688
  • [6] Molecular targeted agents for gastric and gastroesophageal junction cancer
    Takashi Oshima
    Munetaka Masuda
    [J]. Surgery Today, 2012, 42 : 313 - 327
  • [7] Circulating Tumor DNA in Gastric and Gastroesophageal Junction Cancer
    Paschold, Lisa
    Binder, Mascha
    [J]. CURRENT ONCOLOGY, 2022, 29 (03) : 1430 - 1441
  • [8] Advances in the surgical management of gastric and gastroesophageal junction cancer
    Narayan, Raja R.
    Poultsides, George A.
    [J]. TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY, 2021, 6
  • [9] Angiogenic inhibitors in gastric cancers and gastroesophageal junction carcinomas: A critical insight
    Aprile, Giuseppe
    Ongaro, Elena
    Del Re, Marzia
    Lutrino, Stefania Eufemia
    Bonotto, Marta
    Ferrari, Laura
    Rihawi, Karim
    Cardellino, Giovanni Gerardo
    Pella, Nicoletta
    Danesi, Romano
    Fasola, Gianpiero
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2015, 95 (02) : 165 - 178
  • [10] Immune checkpoint inhibitors for treatment of advanced gastric or gastroesophageal junction cancer: Current evidence and future perspectives
    Zhening Zhang
    Tong Xie
    Xiaotian Zhang
    Changsong Qi
    Lin Shen
    Zhi Peng
    [J]. Chinese Journal of Cancer Research, 2020, 32 (03) : 287 - 302
12345